Targeting the IL-4/IL-13 Axis in the Treatment of Type 2 Inflammation

Type 2 inflammation occurs when immune cells, including eosinophils and mast cells, are activated, producing the cytokine IL-4 and Il-13. These cytokines are responsible for signaling the production of eosinophils, mast cells, and IgE antibodies, that lead to the release of more pro-inflammatory cytokines. Type 2 inflammatory conditions affect 10-30% of the global population, and include common conditions such as allergy, asthma, eczema, and eosinophilic esophagitis. By targeting IL-4 and IL-13, overactive immune systems can be regulated, and many patients will see a better quality of life.